Unresectable pancreatic adenocarcinoma: Do we know who survives?

Jamal, MH, Doi, SA, Simoneau, E, Abou Khalil, J, Hassanain, M, Chaudhury, P, Tchervenkov, J, Metrakos, P and Barkun, JS (2010). Unresectable pancreatic adenocarcinoma: Do we know who survives?. In: International Hepato Pancreato Biliary Association Meeting, Buenos Aires, Argentina, (561-566). 18-22 April 2010. doi:10.1111/j.1477-2574.2010.00220.x

Author Jamal, MH
Doi, SA
Simoneau, E
Abou Khalil, J
Hassanain, M
Chaudhury, P
Tchervenkov, J
Metrakos, P
Barkun, JS
Title of paper Unresectable pancreatic adenocarcinoma: Do we know who survives?
Conference name International Hepato Pancreato Biliary Association Meeting
Conference location Buenos Aires, Argentina
Conference dates 18-22 April 2010
Journal name HPB : the official journal of the International Hepato Pancreato Biliary Association   Check publisher's open access policy
Place of Publication Oxford, U.K.
Publisher Wiley-Blackwell Publishing
Publication Year 2010
Sub-type Fully published paper
DOI 10.1111/j.1477-2574.2010.00220.x
ISSN 1365-182X
Volume 12
Issue 8
Start page 561
End page 566
Total pages 6
Collection year 2011
Language eng
Formatted Abstract/Summary
Background:  This study attempts to define clinical predictors of survival in patients with unresectable pancreatic adenocarcinoma (UPA).

Methods:  A retrospective study of 94 consecutive patients diagnosed with UPA from 2001 to 2006 was performed. Using data for these patients, a symptom score was devised through a forward stepwise Cox proportional hazards model based on four weighted criteria: weight loss of >10% of body weight; pain; jaundice, and smoking. The symptom score was subsequently validated in a distinct cohort of 32 patients diagnosed with UPA in 2007.

Results:  In the original cohort, the overall median survival was 9.0 months (95% confidence interval [CI] 7.6–10.4). This altered to 10.3 months (95% CI 6.1–14.5) in patients with locally advanced disease, and 6.6 months (95% CI 4.2–9.0) in patients with distant metastasis. Median survival was 14.6 months (95% CI 13.1–16.1) in patients with a low symptom (LS) score and 6.3 months (95% CI 4.1–8.5) in patients with a high symptom (HS) score. A total of 73% of LS score patients survived beyond 9 months, compared with only 38% of HS score patients (P < 0.001). The discrimination of the LS score was greater than that of any conventional method, including imaging. The validation cohort confirmed the discriminative ability of the symptom score for survival.

  A simple and clinically meaningful point-based symptom score can successfully predict survival in patients with UPA.
Copyright © 1999–2011 John Wiley & Sons, Inc. All Rights Reserved.
Keyword Unresectable pancreatic adenocarcinoma
Surgical palliation
Endoscopic palliation
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Conference Paper
Collections: Official 2011 Collection
School of Public Health Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 8 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Sun, 27 Feb 2011, 00:08:50 EST